18 November 2026 | Wednesday | News
Gibco™ VaxEvo™ CD 293 Medium Collection
Thermo Fisher Scientific, the world leader in serving science, announced the Gibco™ VaxEvo™ CD 293 Medium, a chemically defined and animal origin-free medium designed to support suspension HEK293 cell growth and high-titer adenovirus production. Available in liquid and AGT™ formats, the medium is designed to support vaccine developers from early process development through scale-up and manufacturing.
As suspension-based HEK293 workflows evolve to support scalable adenoviral vectors and adenovirus vaccine production, developers need media that can help deliver strong productivity while reducing process complexity and supporting manufacturing readiness. VaxEvo CD 293 Medium is designed to address these evolving needs.
“Manufacturing readiness begins well before a process reaches the plant. The choices vaccine developers make during process development can shape how they evaluate performance, complexity and the path to scale,” said Alex Cherkassky, vice president and general manager of Thermo Fisher Scientific’s cell culture business. “We developed Gibco VaxEvo CD 293 Medium as a purpose-built starting point to help customers advance suspension-based adenovirus HEK293 processes with greater confidence.”
In laboratory benchmarking studies using HEK293 cells, VaxEvo CD 293 Medium supported average adenovirus type 5 (Ad5) titers comparable to select supplier media, with results reaching up to 5.7-fold higher titers in some comparisons.
The product will be available in liquid and multiple AGT™ package sizes.
Most Read
Bio Jobs
News